BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PT001: Phase IIb data

Top-line data from a double-blind, dose-ranging, U.S. Phase IIb trial in about 100 patients with moderate to severe COPD showed that 4 doses of twice-daily PT001 met the primary endpoint of significantly improving FEV1 AUC from 0-12 hours relative to...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >